MSDC 0160
Alternative Names: Mitoglitazone; MSDC-0160Latest Information Update: 04 Nov 2017
At a glance
- Originator Metabolic Solutions Development Company
- Developer Metabolic Solutions Development Company; PKD Foundation; Van Andel Research Institute
- Class Antihyperglycaemics; Small molecules; Thiazolidinediones
- Mechanism of Action Mitochondrial protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
- No development reported Parkinson's disease; Polycystic kidney disease
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Polycystic-kidney-disease in USA (PO)
- 07 Dec 2016 Van Andel Research Institute and Metabolic Solutions Development Company announce intention to initiate clinical trials for Parkinson's disease in 2017